
Episurf Medical Q2 - Total focus on the US

Redeye provides a more in-depth review of Episurf Medical's Q2 report. Since the company's sales came in lower than expected, we made some downward adjustments to our estimates for the short and medium-term sales forecasts. We revise our base case valuation to SEK1.3 (SEK1.4) per share.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

[Episurf Medical Q2 - Total focus on the US](#)